Page 65 - ITPS-7-4

INNOSC Theranostics

and Pharmacological Sciences

ORIGINAL RESEARCH ARTICLE
The role of saroglitazar in the treatment

of metabolic dysfunction-associated
steatohepatitis in non-diabetic patients: A

prospective observational study

Jata Shankar Kumar*, Priyanshu Bhardwaj, Akul Chadha , and
Premashis Kar*

Department of Medical Gastroenterology, Max Superspeciality Hospital, Vaishali, Ghaziabad, India

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is a metabolic disease
characterized by hepatic fat accumulation and significant inflammation. Patients
with hepatic steatosis who also have at least one of the five cardiometabolic
risk markers are considered to have metabolic dysfunction-associated steatotic
liver disease. MASH is diagnosed when a microscopic examination of liver tissue
reveals fat accumulation in hepatocytes along with inflammation and destruction
*Corresponding authors: of liver cells. This study aims to assess the role of saroglitazar, a dual proliferator
Jata Shankar Kumar peroxisome-activated receptor agonist, in the medical therapy of MASH in non-
(jatashankar.dr@gmail.com)
Premashis Kar diabetic patients. A prospective observational study was carried out in a tertiary
(premashishkar@gmail.com) care facility in north India. A total of 51 non-diabetic MASH patients (males and
females, 18 – 75 years of age, body mass index ≥18.5 kg/m ) were included in this
2
Citation: Kumar JS, Bhardwaj P,
Chadha A, Kar P. The role of study. Diagnosis of MASH was based on liver FibroScan (controlled attenuation
saroglitazar in the treatment parameter [CAP] score >238, liver stiffness measurement [LSM] value >7kPa) along
of metabolic dysfunction- with raised liver enzymes (serum glutamic-oxaloacetic transaminase [SGOT],
associated steatohepatitis in
non-diabetic patients: A prospective serum glutamic-pyruvic transaminase [SGPT] > upper value of normal limits). All
observational study. INNOSC these 51 patients received 4 mg once-daily dose of saroglitazar for the treatment
Theranostics and Pharmacological of MASH for 24 weeks. In this study, a standard treatment protocol was used.
Sciences. 2024;7(4):3560.
doi: 10.36922/itps.3560 The percentage changes in aspartate transaminase (AST), alanine transaminase
(ALT), alkaline phosphatase, triglyceride, low-density lipoprotein (LDL), and
Received: May 1, 2024
LSM with CAP were evaluated using an analysis of variance test and multiple
Accepted: August 13, 2024 regression analysis. About 72.5% of these patients were male and 27.5% were
Published Online: October 4, 2024 female (male: female ratio of 2.6). The mean age of patients was 51 ± 13.13 years.
Pre- and post-treatment values of different parameters were compared. Pre-
Copyright: © 2024 This
is an Open-Access article treatment mean values of ALT and AST were 93.83 ± 6.16 U/L and 76.13 ± 4.1 U/L,
distributed under the terms respectively, while their post-treatment mean values were 32.97 ± 2.15 U/L and
of the Creative Commons 34.57 ± 1.65 U/L, respectively (P-value for AST and ALT <0.001). In conclusion,
AttributionNoncommercial License,
permitting all non-commercial use, saroglitazar is effective in the medical management of MASH by reducing liver
distribution, and reproduction in any stiffness and suppressing elevated liver enzymes (SGOT/SGPT) as well as serum
medium, provided the original work LDL levels over 6 months.
is properly cited.
Publisher’s Note: AccScience
Publishing remains neutral with Keywords: Hepatic steatosis; Hepatocytes; Metabolic dysfunction-associated
regard to jurisdictional claims in steatohepatitis; Proliferator peroxisome activated receptor; Saroglitazar
published maps and institutional
affiliations.

Volume 7 Issue 4 (2024) 1 doi: 10.36922/itps.3560